HUE033294T2 - 2-(azaindol-2-il)benzimidazolok PAD4 inhibitorokként - Google Patents

2-(azaindol-2-il)benzimidazolok PAD4 inhibitorokként Download PDF

Info

Publication number
HUE033294T2
HUE033294T2 HUE12740581A HUE12740581A HUE033294T2 HU E033294 T2 HUE033294 T2 HU E033294T2 HU E12740581 A HUE12740581 A HU E12740581A HU E12740581 A HUE12740581 A HU E12740581A HU E033294 T2 HUE033294 T2 HU E033294T2
Authority
HU
Hungary
Prior art keywords
pyrrolo
formula
compound
mmol
pyridin
Prior art date
Application number
HUE12740581A
Other languages
English (en)
Inventor
Stephen John Atkinson
Michael David Barker
Matthew Campbell
Hawa Diallo
Clement Douault
Neil Stuart Garton
John Liddle
Robert John Sheppard
Ann Louise Walker
Christopher Wellaway
David Matthew Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HUE033294T2 publication Critical patent/HUE033294T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (3)

  1. Saabadaisru igaayfxysxR.
    1. KCpk'i fi) skdxRii vegyxski
    ííbí: : R: kRIikgyö vagy Ct.okkh R; hidrogén. 0;..adkU. parbaknaniH:. :íbkjRí >-. vagy i:: odioaxr. R; hidrogén. C:.sajkái. v agy R: ..RkovoCs .ydldU R.; RkfmgRíR Ckskikk porkarnnedH.': ,..ahoi; vagy sxk>S£ííRk!iRksí Cj.^yklö&amp;lkiiCg^ykksí; A C-R> vagy N; B G-R<. vagy N. ! > C · R .· vagy N : hPiéick.yw. hogv· V B. év j.< kgaRKb égyikh PR R;. hxkogon vagy Γ^οολΗ: R.g hxkogca; vagy {.'_ .gdkii: R· iRdxíígék C·. ...nvd. (V: .gdkoas. vagy hRlsssk By hàlxggà» vagy G; ndk;!. ívik-ckav;.:, hogy k., és R> ygyikg hűk ágén: Rí; igdxygég vagy indxoai: R::. hidrogén vagy CR .ydkil: vagy annak von;. 2. kép ki (I): vasom; vugyüki vagy amxd: aygi a a: 1. hRnypom savant ahöí R; jddxs|Rat
  2. 3. Kap les -B savónk vagykks. vagy aauak aga ua R vagy 2. Igénypuni ssgdgp aPál Ry hidiogon vagy Ci.ndkoxi. 4v Kap ki |!) syyrkP végypk·: vágy axinak sykaa: doao i.gégyp<nséB bánniíiyiks? svaBök ahol R· Cg. y#&amp; 1 Kepki {Bsaekskí yggyekh.vagy RpmR RgsákBökd igdpy|xyB:éKbaBB^ Ru £o odúk. vanbvmnniHadso ét/..cikkvdkdC; gdkd. vagy poni.d;xnckK. ;.:.;.dkil. ;< Kkpki il) gaydpii végyidgí Vkgy· kákák ágik sa doad nknypooxR. haonelyana sáödm,: ahol R.· hidrogén 2: Kép ka · Is sssdnd vegykki vagy rnsnak sigk aa dök.ö ;gvnypooU:k hannoiyikí· vxv'dn; ahoi jR Iddxngém k, Ropie- i\) skgrigk vagyak; vagy anx-nk sgk gg gRRö igagypoxskík hâgnélyiRg svadat,.ahoi R> Igdxpggk, G Kaplak : ; Ï νχνηηϋ vagyuk; vagy sónak agis aa ddkd u-tnypooiok bánnák iko vavnnp khoi :&amp;* hidrogén. us. Renkt (í) >:?vnnSi vagyuk·? v;sg\ snitsk sók Β:ί: eióxó ppkiyponK-k Páresdvik·:- xeensn. drd ksg fpbíbgép. I L R3pks i!} sxdimi: ΐΡργρίρΙ vaf>· s:$B:dk sók 8¾ :L ippdpössi xxcrisV:, arad y ki Visa vàksæks a klkakksôkMy. élk IkkMb i di23 Leó; ifipnnoki kkYÍpkiónr 2-ik ! '·· pspsbdlBPkBb;; s R) - s 3 LkbikL ipdkbP-' 1 31)(2-( 1 -ski - ! H-pksvkf2d-binb'Kiiu-I s IL-1-vec·:;·· : Hkee/<3Bkk<fa,:-d· i Rj-í V-anknapipcaihi? - ! · 3)(3 ·{I dsL ; H pkn;kl I, k;: ipirKkad - d ; 1 -ïîîcsîI ! H-k-snak d ]íí:xL.í.;íx<.-I · k2|)ppkklL iR)RkBB0aspi>PöbssKkii;KLB3dsl:3HlR2.Jk3ki^ ISSÄö[djiöÜdSKi&amp;i:*5~:ji}:®«kiKSS; ÍR ^'í¾-¾kS:l:kL:>:P¾>#Lî4lk;" I 1"C«I^ôi>L«s>âliÎWkïâ:k^:0 IM-:- bvnaoidjisRklakcl· S-Lsnetamsn; {?< ) -1 ·^ í4 ϊ > i 1 ; ?<.>|> i |><;r kt ? - ; · : -ilR 2-(:1 -PS-S dPsksb ' 111 · ρίπο!«! 2 3-b pkrlónkkó)· ! ·η^ηΙ· I Η-bóösó í dl (BkkkpPf-S kl) spsksKSB { RRpnnsniKppcndkl· kó}{2-d nLbkapdnxp !Ü piríde; 23 ·<. Ipisidln-IM!)· kàsksLIlL !>ps®Îs[d|îPIkka:oI--5 blkpskkPR 3k:L H03í-3s:u?ópo· i pnpsrdekjkisHxs'Pkd axkLi (ôbnnxsrddsanl· 2·ό;·ό PI d/p;sT;Bol 13-blpstiilk-'kid; (ILMb'yspbBbplbPRÓkb 1 -b® b ikiil-· I ΐΡρί?ρ4Ρ(23k%PRIP2 - (IL? -aRksi- Í-«kb!- ! K~ bt'ítóvbd;ÍBa<bíaol'5-ü;vaci;jíK;n: (RV{ lauLnopipaviduvi U H 2 ; ! bSibkppRbipkbi)··! I L pindd 3 J -b ipk;<P«-3 -s5>- ”-n«^U><ï - i · PIPbL I ?Τ3>δ:^^|3ρ«3>Ι<:?<Ρ'5'ί!;;:«ίΐ;»··':Β: î:R)‘l3-aî8îB0pîp«ÂB 3-á!K ?bb«P> sbb-B:ps pi-3 b !. b:2: J J-asbRubretb;!'1 k:'pba slPpk-felpibdîkl-· sib I ?[ kI Jsssiiiiss-Äsiil1-5 (^'ppíköpbíbiibPi-b'-blik'iibkbL ifí^bbaíbíby^iLbjRibbbLR-íiL kbkLklBdkftgéidjiPbásköRb' Rksxiksxsn; {pbi4#3-3-asBSpk-bbR:psiplpplkbalkiH3'(i -ikkkpPibiíjtóilbi H-îîîvî;>i;>l I I4>ipsskk-2-ih·? · π<·ηί L : i !b>:'u?;4bbP:Kk?:;4· a d'knxasx·;·!; (1 3kl4.R Ik'BPiüïP·4-hid-xiv iplpeodh;·· ί ·όH 2 ·{ ! bffikb:bsípíiÍBiSfy3> !l:LpsíMkb2k-2s1bí-íbbftk:iib2· sspIPXI-ï-nvïùl· ! B- bépay[d]i skdaköbó31}« sdpaoss >/?H2-:ussíu<spu5aridi;s· 1313,13 i·;:;si· ; B-ps*r<>k223-b:p'ïi'iisv2 -kl· i ·νί;οϊ.ϋ· ? ·(·ϊ5l1îs<.:r:îS';U?^s?d H · feppxpfd bsplôadk· b b bpîkspkb ïA'î i3-xPîSsï>'p!|\s -kl I'Bspîvï\ib-axRPRî ktknpei'pP BPpusdeOdk'jp'irdîivdpLBl' LBax<:ikibi':><i;sxi'i;.3-!ÎjSÎiCî;sT!;MK if 3)-3•xssBssvpipoTkkv i ;Γ=: ' n=ísí ! dPxüi -23I-Ç2-ms bIks isI)- III-pfebps23-Is ipis ftsu:- 2 ·:1)- ill kscssxoikj baibasel k 3}}:mdmsím ; ikyQ-asvstti.-plpznars I 4:(2-1 - Vsl ä 1 1 ·ρ;η44 2 3-4p;nA;s- 2 jî>· 7veea>s!- ; ·( 1: -jííí'í':¾leiHj- Hí-bgs^zylii jií?^ klàæp 1-4 i limelbaga; skik3->aski«^ip^fkls5^!'S:íC2'| l':víil-\IH:-pk;'o|ö|'ih3^P^pSrkipk^'íÍ)'Ρ·;:<<.!ΗβΡ;·';··«;<·ϊ·'>?;;· ;H·· -8mœcs.p5pie'd<lfe~:l“i])(7~ïneî»>iik2~(1/k’2.^n©toxk2-snetiiiîï!S5sii)'vn3'pjrrs3lpf:3ÎS--fe)piriëih-2-'îI|··· b-szsebl4 H k^snx«[P]:hr>kSaKöl~5kl)sasía»os; t.k}k3-aïmsnopsppfiéPï'â 41)(231-isebvbb \ H ' piíto !<s [ ^ 3 -¾ jp i rictjxs · 2 - - j: I} -; Tí - í:í ϊ « ï i> s ΐ -1 -gssul· t H-b«íís;í>[dj kalászéi -44 Imetssren.. és {:Ç«;£>:^-':S---iÎSÎîiiîT£t>---â r xíieísi^s-íperiitlití:-1 - -f-jl '"'f «î kkïfïiXïja í Imetil )~ ^Η-ρχίτα^Ρ,,ν^Ιρ^π^ίη*^*^”?' srsdaxí- i-yaeiil-l lkb®ps<kd!iaidaaskS:'5l)aí8tanpP, és saruik sol 12.: Az 1-11. (gésypeskak Ikbsselvike szemül képlet (I) szeíPui vegyakt gyégyzzeiészekleg elksyadhaíó sókéiü. 13.. 3<épbí (!) szedik! vegyük! asíüly sz 141. Igésypblüol MnePiyíkébesl vaa éefbüáiva, vagy asurak gyógyszvíÁísvfil»g eilvgsdlaíé>lük: ieiksszesfiAs ghüaosatdsé snlzitia, vsseslkl! szfszéíssés ivpus yVYpvovuo.sss. tüceüíüve eoüük ulcemsa. rak, s.rva.ás (thsodv sszOvs. las5;in lapas ssythâmsüôsïsv. vagy ,ρ&amp;ΟΐΧ&amp;^ΐΐΐ.
  3. 14. Clyëgyzztsdszeü kosüpozfclü, amelyiadstmaz képiéi (!> szemül vegyükk! assay az l-ií, ígéoypóstok báneelytkébea vm. áeSi#!*», vsgy assek gyógyszetészetüeg ellygíSílkató sips és égy vagy több gyogyszerézzeüleg diegsbbsG empans?.
HUE12740581A 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazolok PAD4 inhibitorokként HUE033294T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors
EP12740581.9A EP2877467B1 (en) 2012-07-26 2012-07-26 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
HUE033294T2 true HUE033294T2 (hu) 2017-11-28

Family

ID=49996626

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12740581A HUE033294T2 (hu) 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazolok PAD4 inhibitorokként

Country Status (22)

Country Link
US (4) US9127003B2 (hu)
EP (1) EP2877467B1 (hu)
JP (1) JP6063567B2 (hu)
KR (1) KR101916443B1 (hu)
CN (1) CN104470919B (hu)
AU (1) AU2012386257B2 (hu)
BR (1) BR112015001545B1 (hu)
CA (1) CA2879341C (hu)
CY (1) CY1118524T1 (hu)
DK (1) DK2877467T3 (hu)
ES (1) ES2609126T3 (hu)
HR (1) HRP20161530T1 (hu)
HU (1) HUE033294T2 (hu)
IN (1) IN2014KN02935A (hu)
LT (1) LT2877467T (hu)
PL (1) PL2877467T3 (hu)
PT (1) PT2877467T (hu)
RS (1) RS55684B1 (hu)
RU (1) RU2611010C2 (hu)
SI (1) SI2877467T1 (hu)
SM (1) SMT201700052B (hu)
WO (1) WO2014015905A1 (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3199601A1 (en) * 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
SG11201807021UA (en) * 2016-02-23 2018-09-27 Padlock Therapeutics Inc Heteroaryl inhibitors of pad4
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
JP6987843B2 (ja) * 2016-07-27 2022-01-05 パドロック・セラピューティクス・インコーポレイテッドPadlock Therapeutics, Inc. Ｐａｄ４の共有結合性阻害剤
KR102502992B1 (ko) * 2016-09-12 2023-02-24 패들락 테라퓨틱스, 인코포레이티드 Pad4의 헤테로아릴 억제제
WO2018102262A1 (en) * 2016-12-02 2018-06-07 University Of Massachusetts Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
CA3073656C (en) 2017-09-22 2024-03-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) * 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
KR20200092346A (ko) 2017-11-24 2020-08-03 주빌런트 에피스크라이브 엘엘씨 Prmt5 억제제로서의 헤테로사이클릭 화합물
JP2021515043A (ja) * 2018-02-26 2021-06-17 南京薬捷安康生物科技有限公司Ｎａｎｊｉｎｇ Ｔｒａｎｓｔｈｅｒａ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏ．， Ｌｔｄ． ペプチジルアルギニンデイミナーゼ阻害剤及びその使用
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物
EA202190464A1 (ru) * 2018-08-08 2021-06-16 Бристол-Маерс Сквибб Компани Замещенные бензимидазолы в качестве ингибиторов pad4
EA202190462A1 (ru) 2018-08-08 2021-06-03 Бристол-Маерс Сквибб Компани Индольные и азаиндольные ингибиторы ферментов pad
WO2020033514A1 (en) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Benzimidazole inhibitors of pad enzymes
ES2929200T3 (es) 2018-08-08 2022-11-25 Bristol Myers Squibb Co Tienopirroles sustituidos como inhibidores de PAD4
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
US20230002328A1 (en) * 2019-07-03 2023-01-05 University Of Massachusetts Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof
CN112574230B (zh) * 2019-09-27 2022-10-28 药捷安康(南京)科技股份有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
CN115298175B (zh) * 2020-02-06 2024-05-07 百时美施贵宝公司 可用作免疫抑制剂的大环pad4抑制剂
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
CA3177532A1 (en) * 2020-04-30 2021-11-04 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
EP4211171A2 (en) 2020-09-10 2023-07-19 Precirix N.V. Antibody fragment against fap
EP4215534A1 (en) 2020-09-18 2023-07-26 Sumitomo Pharma Co., Ltd. Amine derivative
WO2022140390A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202329941A (zh) 2021-11-15 2023-08-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｐａｄ４抑制劑及其用途
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
WO2023230609A1 (en) * 2022-05-26 2023-11-30 Celgene Corporation Heterocyclic pad4 inhibitors
WO2024109945A1 (en) * 2022-11-24 2024-05-30 Helios Huaming Biopharma Co., Ltd. Selenium containing heterocycle compounds and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
EP1157749B1 (en) 1995-04-14 2007-09-19 SmithKline Beecham Corporation Proces for preparing a metered dose inhaler
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
BR9913888A (pt) * 1998-09-18 2002-01-08 Basf Ag Composto, e, métodos de inibir a atividade da proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
CA2387840A1 (en) * 1999-10-19 2001-04-26 Scott R. Hambaugh Tyrosine kinase inhibitors
SK287882B6 (sk) 1999-12-24 2012-02-03 Aventis Pharma Limited Azaindoles derivatives, pharmaceutical composition containing thereof and their use
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
WO2005044354A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
WO2005047289A1 (en) 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
EP2205085A1 (en) * 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
US20090311217A1 (en) 2008-05-28 2009-12-17 Wyeth 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
EP2414328B1 (en) 2009-04-02 2021-05-26 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using

Also Published As

Publication number Publication date
US9518054B2 (en) 2016-12-13
BR112015001545B1 (pt) 2022-07-05
WO2014015905A1 (en) 2014-01-30
US20160009716A1 (en) 2016-01-14
JP6063567B2 (ja) 2017-01-18
US20150175600A1 (en) 2015-06-25
US20180161316A1 (en) 2018-06-14
LT2877467T (lt) 2017-01-10
CN104470919A (zh) 2015-03-25
CA2879341A1 (en) 2014-01-30
KR101916443B1 (ko) 2018-11-08
US9833449B2 (en) 2017-12-05
US20170119750A1 (en) 2017-05-04
HRP20161530T1 (hr) 2017-02-10
RU2611010C2 (ru) 2017-02-17
RU2014152456A (ru) 2016-09-20
CN104470919B (zh) 2016-07-06
AU2012386257A1 (en) 2015-03-12
EP2877467A1 (en) 2015-06-03
DK2877467T3 (en) 2017-02-13
PL2877467T3 (pl) 2017-08-31
KR20150038438A (ko) 2015-04-08
CA2879341C (en) 2019-06-11
SMT201700052B (it) 2017-03-08
BR112015001545A2 (pt) 2017-07-04
JP2015522628A (ja) 2015-08-06
PT2877467T (pt) 2017-01-02
IN2014KN02935A (hu) 2015-05-08
US10039755B2 (en) 2018-08-07
ES2609126T3 (es) 2017-04-18
EP2877467B1 (en) 2016-11-02
CY1118524T1 (el) 2017-07-12
SI2877467T1 (sl) 2017-02-28
AU2012386257B2 (en) 2016-09-08
RS55684B1 (sr) 2017-07-31
US9127003B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
DK2877467T3 (en) 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS
EP3298003B1 (en) Benzoimidazole derivatives as pad4 inhibitors
US11426412B2 (en) Imidazo-pyridine compounds as PAD inhibitors
EA037753B1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
AU2014374043A1 (en) TRPA1 modulators
TW202204343A (zh) 經取代之３－苯氧基氮雜環丁烷－１－基－吡